Richard Francis

Richard Francis, Teva's President and CEO, discusses his transformative journey at the helm. Over two and a half years, he has driven a 'Pivot to Growth' strategy, navigating challenges to achieve nine quarters of growth. Francis highlights Teva's innovative medicines like Austedo and Ajovy aimed at unmet medical needs, while also addressing the importance of expanding generics and biosimilars internationally. With a focus on modernization and a $700 million cost reduction, he shares insights into fostering long-term growth and staying committed to patient care.